Each vial of Uracyst® contains 400 mg of chondroitin sulfate in a sterile 20 mL solution. This small 20 mL volume makes it easier for an IC patient to hold post instillation. It is recommended that the patient holds the solution for a minimum of thirty (30) minutes or as long possible before voiding. Patients will find that they can hold the solution for longer periods of time as the treatment schedule progresses.
Results from experimental animal studies suggest that the human IC bladder requires at least 300 mg of chondroitin sulfate to fully saturate the bladder in a single instillation4. Uracyst® contains 400 mg of chondroitin sulfate which should be sufficient to allow the damaged bladder to reach the saturation point of chondroitin sulfate with each instillation.
The typical instillation procedure is as follows:
- The patient should lay on their back
- Using a standard technique, insert a lubricated urinary catheter (8 – 10 gauge) into the bladder via the urethra
- Lower the open end of the catheter so that any residual urine is drained from the bladder into a receptacle for disposal
- Elevate the open end of the catheter and insert a sterile funnel or sterile syringe with the plunger removed, and pour in the Uracyst®
- Once the Uracyst® has been instilled, remove the catheter and instruct the patient to hold the Uracyst® in their bladder for as long as possible, but at least for thirty (30) minutes
- The patient can be released immediately after the instillation
Intravesical instillation of Uracyst® should be done once a week for 6 weeks and then monthly thereafter until symptoms resolve. Patients experiencing a flare while on monthly therapy should revert to weekly therapy until such time as the symptoms resolve. The duration of therapy will vary from patient to patient.